Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma

References

• Stratigos A, Garbe C, Lebbe C, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(14):1989–2007.
   PubMed Web of Science ®Google Scholar
• Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–351.
   PubMed Web of Science ®Google Scholar
• Waldman A, Schmults C. Cutaneous squamous cell carcinoma. Hematol Oncol Clin North Am. 2019;33(1):1–12.
   PubMed Web of Science ®Google Scholar
• Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018;78(2):237–247.
   PubMed Web of Science ®Google Scholar
• Brougham NDL, Tan ST. The incidence and risk factors of metastasis for cutaneous squamous cell carcinoma–implications on the T-classification system. J Surg Oncol. 2014 Dec;110(7):876–882.
   PubMed Web of Science ®Google Scholar
• Leiter U, Eigentler T, and Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol. 2014;810:120–140.
   PubMedGoogle Scholar
• Breuninger H, Eigentler T, Bootz F, et al. Brief S2k guidelines–Cutaneous squamous cell carcinoma. J der Dtsch Dermatologischen Gesellschaft = J Ger Soc Dermatology JDDG. 2013 Jun;11(Suppl s3):37–47.
   PubMedGoogle Scholar
• Corchado-Cobos R, García-Sancha N, González-Sarmiento R, et al. Cutaneous squamous cell carcinoma: from biology to therapy. Int J Mol Sci. 2020;21(8):8.
   Web of Science ®Google Scholar
• Brash DE, Ziegler A, Jonason AS, et al. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J Investig Dermatology Symp Proc. 1996 Apr;1(2):136–142.
   PubMedGoogle Scholar
• South AP, Purdie KJ, Watt SA, et al. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. J Invest Dermatol. 2014 Oct;134(10):2630–2638.
   PubMed Web of Science ®Google Scholar
• Brown VL, Harwood CA, Crook T, et al. p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. J Invest Dermatol. 2004 May;122(5):1284–1292.
   PubMed Web of Science ®Google Scholar
• Cañueto J, Cardeñoso E, García JL, et al. Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma. Br J Dermatol. 2017 May;176(5):1279–1287.
   PubMed Web of Science ®Google Scholar
• García-Sancha N, Corchado-Cobos R, Pérez-Losada J, et al. Dysregulation in cutaneous squamous cell carcinoma. Int J Mol Sci. 2019 May;20(9):9.
   Web of Science ®Google Scholar
• Bottomley MJ, Thomson J, Harwood C, et al. The role of the immune system in cutaneous squamous cell carcinoma. Int J Mol Sci. 2019;20(8):2009.
   PubMed Web of Science ®Google Scholar
• Rischin D, Migden MR, Lim AM, et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020;8(1):1.
   Web of Science ®Google Scholar
• Chikuma S, Terawaki S, Hayashi T, et al. PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J Immunol. 2009 Jun;182(11):6682–6689.
   PubMed Web of Science ®Google Scholar
• Flies DB, Sandler BJ, Sznol M, et al. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med. 2011 Dec;84(4):409–421.
   PubMedGoogle Scholar
• Gerlini G, Romagnoli P, Pimpinelli N. Skin cancer and immunosuppression. Crit Rev Oncol Hematol. 2005 Oct;56(1):127–136.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Libtayo (cemiplimab): summary of product characteristics. 2019.
   Google Scholar
• Regeneron Pharmaceuticals. Libtayo (cemiplimab): US prescribing information. 2018.
   Google Scholar
• Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992 Nov;11(11):3887–3895.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000 Oct;192(7):1027–1034.
   PubMed Web of Science ®Google Scholar
• Burova E, Hermann A, Waite J, et al. Characterization of the anti-PD-1 antibody REGN2810 and Its antitumor activity in Human PD-1 knock-in mice. Mol Cancer Ther. 2017;16(5):861–870.
   PubMed Web of Science ®Google Scholar
• Yang F, Paccaly AJ, Rippley RK, et al. Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies. J Pharmacokinet Pharmacodyn Internet. 2021;48(4):479–494.
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Papadopoulos KP, Johnson ML. Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): longer follow-up efficacy and safety data. Ann Oncol. 2018;29(December):x24.
   Google Scholar
• Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21(2):294–305.
   PubMed Web of Science ®Google Scholar
• Migden MR, Chandra S, Rabinowits G, et al. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma. Futur Oncol. 2020;16(4):11–19.
   PubMed Web of Science ®Google Scholar
• Guillaume T, Puzenat E, Popescu D, et al. Cemiplimab‐rwlc in advanced cutaneous squamous cell carcinoma: a real‐life experience in a French dermatology department. Br J Dermatol. 2021;0–1.
   Web of Science ®Google Scholar
• Tsung I, Worden FP, Fontana RJ. Study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma. Oncologist. 2021;26(2):133–138.
   PubMed Web of Science ®Google Scholar
• Estenaga A, Castañón E, García-Martínez FJ, et al. Cutaneous squamous cell carcinoma presenting with facial paralysis: good response to Cemiplimab. JDDG - J Ger Soc Dermatology. 2021;19(3):448–450.
   Web of Science ®Google Scholar
• Rubatto M, Merli M, Avallone G, et al. Immunotherapy in xeroderma pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review. Oncotarget. 2021;12(11):1116–1121.
   PubMedGoogle Scholar
• Khaddour K, Gorell ES, Dehdashti F, et al. Induced remission of metastatic squamous cell carcinoma with an immune checkpoint inhibitor in a patient with recessive dystrophic epidermolysis bullosa. Case Rep Oncol. 2020;13(2):911–915.
   PubMed Web of Science ®Google Scholar
• Nelson R, Luu L, Silberstein P, et al. Novel treatment of locally advanced cutaneous squamous cell carcinoma with cemiplimab: a case report. Int J Dermatol. 2021;60(2):233–235.
   PubMed Web of Science ®Google Scholar
• Escobar GF, Granel-Brocard F, Schmutz JL, et al. Simultaneous response of cutaneous and lung squamous cell carcinoma with cemiplimab. Dermatol Ther. 2020;33(6):3–5.
   Web of Science ®Google Scholar
• Cervantes JA, Fox MC. Successful treatment of recurrent advanced cutaneous squamous cell carcinoma with cemiplimab. Dermatol Online J. 2020;26(10):0–4.
   Google Scholar
• Paoluzzi L, Ow TJ. Safe administration of cemiplimab to a kidney transplant patient with locally advanced squamous cell carcinoma of the scalp. Curr Oncol. 2021;28(1):574–580.
   PubMed Web of Science ®Google Scholar
• Marukian NV, Lin JQ, Colevas AD, et al. Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma. JAAD Case Rep Internet. 2020;6(9):1279–1287.
   Google Scholar
• Rose AN, Yilmaz E, Durkin JR. Intravascular squamous cell carcinoma treated with cemiplimab. JAAD Case Rep Internet. 2021;14:82–84.
   PubMed Web of Science ®Google Scholar
• Rorive A, Piret P, Quatresooz P, et al. Carcinome spinocellulaire cutané localement avancé et métastatique traité par cémiplimab. (1):436–440.
   Google Scholar
• Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):341–351.
   PubMedGoogle Scholar
• Keeping S, Xu Y, Chen CI, et al. Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma. Futur Oncol. 2021;17(5):861–870.
   Web of Science ®Google Scholar
• Konidaris G, Paul E, Kuznik A, et al. Assessing the value of cemiplimab for adults with advanced cutaneous squamous cell carcinoma: a cost-effectiveness analysis. Value Heal. 2021;24(3):viii461–viii462.
   Web of Science ®Google Scholar
• Ghetti G, D’avella MC, Pradelli L. Preliminary cost-effectiveness and cost-utility analysis of cemiplimab in patients with advanced cutaneous squamous cell carcinoma in Italy. Clin Outcomes Res. 2021;26:133–138.
   Google Scholar
• Valentin J, Gérard E, Ferte T, et al. Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma. J Geriatr Oncol Internet. 2021;12(7):1110–1113.
   PubMed Web of Science ®Google Scholar
• Virgen CA, Nguyen TA, Di Raimondo C, et al. Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma. JAAD Case Rep Internet. 2020;6(3):911–915.
   Google Scholar
• Jeyakumar N, Etchegaray M, Henry J, et al. The terrible triad of checkpoint inhibition: a case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma. Case Reports Immunol. 2020;2020:1–4.
   Web of Science ®Google Scholar
• Patel R, Chang ALS. Immune checkpoint inhibitors for treating advanced cutaneous squamous cell carcinoma. Am J Clin Dermatol. 2019;20(4):477–482.
   PubMed Web of Science ®Google Scholar
• Barrios DM, Do MH, Phillips GS, et al. Immune checkpoint inhibitors to treat cutaneous malignancies. J Am Acad Dermatol. 2020;83(5):1239–1253.
   PubMed Web of Science ®Google Scholar